KURA

Kura Oncology, Inc. (KURA) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer. The company recently transitioned to a commercial-stage organization following the FDA approval of its first product, KOMZIFTI (ziftomenib), in November 2025 for the treatment of relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 29.5% year-over-year, driven by the initiation of commercial sales of KOMZIFTI, which generated $5.8 million in product revenue in Q1 2026 (the first full quarter of commercialization). Collaboration revenue decreased slightly to $12.5 million due to the recognition timing of development services under the Kyowa Kirin agreement.
• Increased Expenses: Operating expenses rose to $97.1 million from $78.8 million. Research and Development (R&D) expenses increased by $9.3 million, primarily due to costs associated with ziftomenib combination trials and the darlifarnib Phase 1 trial. Selling, General, and Administrative (SG&A) expenses increased by $8.7 million, reflecting higher personnel costs and sales/marketing expenses for the new commercial launch.
• Cash Position: Cash and cash equivalents decreased significantly from $149.1 million to $39.1 million, while short-term investments increased slightly. The net decrease in cash of $110.0 million was driven by net cash used in operating activities ($85.9 million) and investing activities ($24.2 million).

Outlook, Guidance, and Risks

• Liquidity: Management believes current cash, cash equivalents, and short-term investments ($580.8 million) combined with anticipated payments under the Kyowa License Agreement ($180.0 million) will fund operations into the fourth quarter of 2027 and advance the ziftomenib AML program through the first topline results from the KOMET-017 trials, anticipated in 2028.
• Commercialization: The company has secured parity coverage for over 93% of covered lives in the U.S. for KOMZIFTI. Several private payors require patients to step through KOMZIFTI first before other menin inhibitors.
• Clinical Pipeline:
  • Ziftomenib: Advancing Phase 3 trials (KOMET-017) in frontline AML (both intensive and non-intensive chemotherapy settings). Topline results for the accelerated endpoint in the intensive setting are anticipated in 2028.
  • Darlifarnib: Phase 1 trials in combination with cabozantinib (RCC) and adagrasib (NSCLC, CRC, PDAC) are ongoing. Preliminary data in RCC showed an objective response rate of 44% in patients previously treated with cabozantinib.
• Risks: Key risks include the ability to successfully commercialize KOMZIFTI, dependence on the Kyowa Kirin collaboration for global development and U.S. co-promotion, potential delays in clinical trials, and the need for substantial additional capital in the future. The company also faces risks related to third-party manufacturing and supply chain disruptions.

Investor Verification Checklist

• Verify the sustainability of KOMZIFTI sales velocity and reimbursement rates beyond the first full quarter of commercialization.
• Monitor enrollment progress and data readouts for the KOMET-017 Phase 3 trials, which are critical for expanding the addressable market beyond relapsed/refractory settings.
• Assess the performance of the Kyowa Kirin collaboration, specifically regarding co-promotion obligations in the U.S. and development progress outside the U.S.
• Review the burn rate relative to the $580.8 million cash position to confirm the runway into late 2027 without additional financing.
• Track the progress of the darlifarnib program, particularly the combination with cabozantinib in renal cell carcinoma, as a potential diversification of revenue streams.